Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

 

Source:  Actinium Pharmaceuticals, Inc. 11/18/2024

-  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia

-  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes

-  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025

-  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed or refractory acute myeloid leukemia

-  Accomplished biopharma industry executive June Almenoff, M.D., Ph.D., appointed to Actinium's Board of Directors  

-  Cash and cash equivalents of approximately $78.6 million as of September 30, 2024, is expected to fund operations into 2027

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial results for the third quarter ended September 30, 2024. Iomab-B is a first in class CD45 targeted conditioning agent to enable bone marrow transplant (BMT) and has been studied in over four hundred patients including the completed Phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia (r/r AML). Actimab-A is a targeted radiotherapeutic that uses the Actinium-225 (Ac-225) isotope payload directed against CD33 with broad potential for development in AML and other myeloid indications including in collaboration with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA). Iomab-ACT is a next-generation CD45 targeted conditioning agent being developed for cell and gene therapies for both malignant and non-malignant hematologic indications. Actinium is executing cutting-edge R&D focused on ARCs and other targeted radiotherapies for blood cancer and solid tumor indications leveraging its strong intellectual property portfolio of 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

Sandesh Seth, Actinium's Chairman and CEO, stated, "During the third quarter and over the last several weeks, we have made significant progress with our three ARC clinical programs. Actinium is now positioned to advance exciting clinical trials for Actimab-A and Iomab-ACT in large indications with high unmet needs that can deliver impactful clinical data in 2025. Actimab-A's backbone therapy potential is poised to be realized with the operationally seamless Phase 2/3 trial following alignment with the FDA, additional clinical trials being planned under the NCI CRADA including the myeloMATCH program and via our R&D efforts to further elucidate Actimab-A's mutation agnostic mechanism of action. The clinical data anticipated from Iomab-ACT in 2025 from the commercial CAR-T and sickle cell transplant trials has the potential to establish Iomab-ACT as a best-in-class targeted conditioning agent for both malignant and non-malignant hematology indications. In addition, our recent meeting with the FDA regarding Iomab-B established a clear development pathway, which will be incredibly valuable in securing a U.S. strategic partner. Finally, I am delighted to welcome Dr. June Almenoff to our Board of Directors, who brings over 25 years of biopharma industry experience with a proven track record of leading drug development through approvals and executing value enhancing business development transactions."

Actimab-A Regulatory and Development Update

• Actinium met with the FDA in the third quarter and aligned with the FDA on an operationally seamless randomized Phase 2/3 trial to study Actimab-A + CLAG-M
• In the Phase 2 portion of the study, the Actimab-A dose will be optimized in combination with CLAG-M
• The Phase 3 portion will study the optimized dose of Actimab-A + CLAG-M versus CLAG-M alone in patients with r/r AML
• Operationally seamless trial design is expected to reduce the required time and resources compared to separate Phase 2 and Phase 3 trials
• Actinium continues to evaluate and develop additional Actimab-A clinical trials under its CRADA with the NCI, investigator initiated, or Actinium sponsored studies
• Actimab-A selected by NCI for recently opened myeloMATCH precision medicine program for patients with AML and myelodysplastic syndrome (MDS)

Iomab-ACT Program Update

• In the third quarter, the FDA cleared the investigational new drug (IND) applications for both the commercial CAR-T study led by the University of Texas Southwestern (UTSW) and the sickle cell trial being led by Columbia University
• The UTSW commercial CAR-T trial expected to initiate patient enrollment in 1Q 2025 with proof-of-concept clinical data expected by year end
• Commercial CAR-T sales exceeded $3.5 billion in 2023 with multiple CAR-T therapies approved for patients with lymphomas, leukemias and multiple myeloma
• Columbia University sickle cell transplant trial to study Iomab-ACT for targeted conditioning prior to BMT for the first time in a non-malignant hematology setting, which is a rapidly growing indication for BMT; patient enrollment expected to commence in the first half of 2025

Iomab-B Regulatory Status and Program Update

• Actinium is seeking a U.S. strategic partner to advance clinical development of Iomab-B including the Phase 3 trial
• Actinium met with the FDA in the fourth quarter and aligned on the patient population for the head-to-head Phase 3 trial to evaluate allogeneic BMT using Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation (Flu/TBI) versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI
• Head-to-head Phase 3 trial to enroll adult patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%, representing a broader patient population than that in the SIERRA trial
• Dose optimization trial to be completed prior to initiating the head-to-head Phase 3 trial to determine the dose for Iomab-B based on radiation to the bone marrow rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based on several interactions with the FDA before starting the SIERRA trial

Mr. Seth added, "We are excited by our recent progress and committed to delivering on several milestones in the near-term and throughout 2025. Our current balance sheet provides strong runway into 2027, which enables us to deliver important clinical data and further realize our vision of being a leading fully integrated specialty radiopharmaceutical company."

Third Quarter 2024 Financial Results

Cash and cash equivalents of approximately $78.6 million as of September 30, 2024. Based on Actinium's current operating plan, cash and cash equivalents are expected to fund operations into 2027.

Research and Development Expense, net of reimbursements

Research and development expenses of $9.8 million for the three months ended September 30, 2024 decreased $1.8 million from $11.6 million for the three months ended September 30, 2023. The decrease is primarily a result of a decline in Chemistry, manufacturing and controls, or CMC, expenses of $5.5 million and lower consulting expenses of $0.5 million, both due to lower activity in 2024 related to Iomab-B. These declines were partially offset by increased preclinical expenses of $3.9 million.

General and administrative expense 

General and administrative expenses of $2.8 million for the three months ended September 30, 2024 increased by $0.1 million from $2.7 million for the three months ended September 30, 2023, primarily due to higher non-cash stock compensation expense of $0.5 million, partially offset by lower compensation expense of $0.3 million due to lower headcount.

In the third quarter of 2024, our overall headcount reduced by approximately twenty percent, with a majority of these former employees being from our clinical and CMC groups. As a result of these departures, we expect our personnel expenses to be reduced by approximately $3.7 million in 2025, which may be offset by additional hires or consultants. We do not expect these departures to have a material impact on our operations or ability to execute our operating plan and we are actively seeking a strategic partner for Iomab-B in the U.S. to advance the clinical development activity for Iomab-B including the planned Phase 3 trial.

Other income

Other income is comprised of net interest income in both reporting periods. The amount for the three months ended September 30, 2024 and 2023 of $1.0 million in each reporting period was virtually unchanged from the same time period in the prior year.

Net loss

Net loss of $11.6 million for the three months ended September 30, 2024 decreased by $1.7 million from $13.3 million for the three months ended September 30, 2023 due to lower research and development expenses partially offset by higher general and administrative expenses.

About Actinium Pharmaceuticals, Inc.

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium is seeking a potential strategic partner for in the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

 

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

 

Source:  Actinium Pharmaceuticals, Inc. 11/4/2024

Dr. Almenoff brings more than 25 years of drug development and leadership
experience to the Actinium Board of Directors  

-       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to numerous biopharma companies. 

Sandesh Seth, Actinium's Chairman and CEO, stated, "Through her career, June has amassed significant experience in translational research, drug development and business development that has resulted in multiple approved products and value creation. Her experience will be invaluable to Actinium and we are delighted to add Dr. Almenoff to the Actinium Board."

Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now AbbVie) for $1.2B. Furiex developed eluxadoline (Viberzi®), which was approved both in the United States and Europe. She also served as Chief Medical Officer of RedHill Biopharma Ltd (Nasdaq: RDHL) leading a team whose work led to the recognition of Talicia® as a first-line therapy for H. pylori.  Earlier in her career, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. She also led the development of pioneering data analytics systems, which have been widely adopted by industry and regulators to minimize clinical risk for pharmaceutical products.

Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development across many therapeutic areas, and has led or contributed to numerous regulatory submissions, product approvals and launches. She is a member of the investment advisory board of the Harrington Discovery Institute, a director on the board of Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Tenax Therapeutics (Nasdaq: TENX).

Dr. Almenoff added, "Targeted radiotherapy has become an important treatment option for patients in multiple oncology indications, which I believe will only continue to expand. I am impressed by Actinium's innovative R&D, clinical development experience and capabilities, as well as its proprietary Actinium-225 manufacturing technology. Collectively, Actinium has the vision and components to become a leading fully integrated specialty radiopharmaceutical company. I am excited to join the Actinium Board and look forward to working to help the company realize its vision and create value for patients and shareholders alike."

Dr. Almenoff received her B.A. cum laude from Smith College and graduated with Alpha Omega Alpha honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.

About Actinium Pharmaceuticals, Inc.

Actinium develops Antibody Radiation Conjugates ("ARCs") and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ("r/r AML"), which Actinium is seeking a potential strategic partner for in the U.S. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ("NCI") under the Cooperative Research and Development Agreement ("CRADA") for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds more than 235 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

 

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

 

Source:  Actinium Pharmaceuticals, Inc. 9/20/2024

• Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approaches
• SIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significance
• Iomab-B was well tolerated in the older, heavily pretreated relapsed/refractory AML patients with active disease enrolled in the SIERRA trial
• Actinium to seek strategic partner for Iomab-B for further development in the U.S. following completion of interactions with FDA for additional head-to-head clinical trial to demonstrate overall survival benefit

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the publication of the Phase 3 SIERRA results of Iomab-B in the peer-reviewed Journal of Clinical Oncology (JCO). The article, titled, "Randomized Phase III SIERRA Trial of ¹³¹I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation vs Conventional Care for Relapsed/Refractory Acute Myeloid Leukemia" and is available online on the ASCO Journal of Clinical Oncology website HERE.

The Phase 3 SIERRA (Study of Iomab-B in Elderly Relapsed Refractory AML) trial was a randomized, multi-center, controlled trial that enrolled 153 patients aged 55 and above with active relapsed or refractory Acute Myeloid Leukemia (r/r AML), including heavily pre-treated patients and those with high-risk characteristics such as a TP53 mutation. The SIERRA trial compared outcomes of patients receiving Iomab-B (Iodine-131-apamistamab) and a bone marrow transplant (BMT) to physician's choice of salvage chemotherapy and standard allogeneic BMT in the control arm.

The SIERRA trial met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001) with 22% of patients (13/76) achieving dCR in the Iomab-B arm compared to 0% of patients (0/77) in the control arm. A significant improvement in Event Free Survival (EFS), a secondary endpoint of the SIERRA trial with a Hazard Ratio = 0.22 (p-value <0.0001) was also achieved. SIERRA did not meet the secondary endpoint of overall survival (OS) on an intent to treat basis analysis due to the high crossover rate with nearly 60% of control arm patients receiving Iomab-B followed by a BMT. 

The Phase 3 SIERRA results were first presented in a late-breaker presentation at the Transplantation & Cellular Therapy (TCT) Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in February 2023. Since TCT, the results of the SIERRA trial have been presented in several oral presentations at leading BMT, hematology, nuclear medicine and nursing meetings and congresses in the U.S. and EU. Supplemental analyses of the SIERRA results have shown improved survival outcomes in patients with a TP53 mutation, which is associated with poor outcomes, as well as increased 1-and 2-year overall survival in patients aged 65 and above.

Dr. Sergio Giralt, Deputy Division Head, Division of Hematological Malignancies and Attending Physician, Adult BMT Service at the Memorial Sloan Kettering Cancer Center, and leading SIERRA Trial investigator and corresponding author, said, "The SIERRA trial was important for the field of transplant and demonstrated for the first time in a randomized study that the CD45 antibody-radioconjugate Iomab-B can provide patients with improved access to a potentially curative hematopoietic stem cell transplant, and improved outcomes compared to current chemotherapy-based regimens. Importantly, Iomab-B demonstrated a statistically significant improvement in key efficacy endpoints including durable Complete Remission and event-free survival. The SIERRA trial was conducted as multiple new therapies gained approval and was designed to address the nuances and difficulty of treating this patient population including allowing physician's choice of care in the control arm given the heterogeneity of treatment across institutions and the crossover design to provide best patient care. Despite multiple drug approvals for patients with AML, there remains no curative options for older patients with relapsed or refractory disease and outcomes for these patients also remain dismal. My fellow investigators and I are disappointed that the SIERRA trial will not support the approval of Iomab-B despite the positive results and significant unmet medical need of this patient population. However, there is continued significant interest from the transplant community to participate in the upcoming phase 3 study with Iomab-B to provide patients access to this important drug candidate."

On August 05, 2024, Actinium announced that after concluding both its clinical and Chemistry, Manufacturing and Controls ("CMC") interactions with the FDA regarding the BLA pathway for Iomab-B, the FDA determined that demonstrating an overall survival benefit in a randomized head-to-head trial is required for a BLA filing, and the SIERRA trial alone will not be adequate for BLA filing.

Sandesh Seth, Actinium's Chairman and CEO, stated, "We are excited that the SIERRA results have been published in the peer-reviewed Journal of Clinical Oncology. We believe the SIERRA trial was a major advancement for the field of BMT and targeted radiotherapeutics but most importantly for patients with relapsed and refractory AML. We look forward to completing our interactions with the FDA to finalize the specifics of the additional Phase 3 randomized trial and working to secure a U.S. partner for Iomab-B. In doing so, we hope to accelerate Iomab-B reaching patients with high unmet need that can benefit from a bone marrow transplant."

About Actinium Pharmaceuticals, Inc.

Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B, an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

 

Venu Holding Corporation Introduces New Structured Financing Model to Accelerate Sales Growth of its Luxury Fire Pit Suites, Expanding Access to Exclusive Ownership Opportunities

 

Source:  Venu Holding Corporation 2/19/2025

The Strategic Initiative Expands Access to High-Demand Luxury Suites Through Fractional Ownership While Driving Capital-Efficient Growth for VENU 

 

Venu Holding Corporation ("VENU" or the “Company”) (NYSE American: VENU), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, today announced the launch of its innovative structured financing model designed to accelerate the expansion of its highly sought-after Fire Pit Suites—luxury VIP seating areas that combine the exclusivity and luxe suite ambiance with a private fire pit lounge setting.  

Expanding Ownership Opportunities

This new structured financing approach provides flexible payment options for buyers of rights to Fire Pit Suites, making these suites accessible to a broader audience. Previously, ownership was limited to those able to purchase an entire suite outright. Now, buyers can access structured payment plans and finance their purchase over time. This structure allows more people to participate in VENU’s premium entertainment experiences while supporting the Company’s broader venue expansion strategy.

“From day one, our Fire Pit Suites have set the gold standard for premium live entertainment,” said J.W. Roth Founder, Chairman, and CEO of VENU. “Demand for these exclusive opportunities soars the moment they become available—they are, without a doubt, our most sought-after and best-selling ownership offering. Our new financing model turns up the heat, making it easier than ever for more buyers to claim their stake in our premium venues, experience world-class entertainment, and participate in revenue-sharing opportunities—while fueling our expansion in high-growth markets.”

A Capital-Efficient Growth Strategy

VENU’s new structured financing model aligns with its broader capital-efficient growth strategy. Unlike traditional entertainment venue developers that rely on extensive debt financing, VENU has pioneered a unique public-private partnership model, securing municipal support and financial incentives that reduce upfront capital expenditures. Additionally, pre-sales of naming rights, sponsorships, and Fire Pit Suites serve as critical funding sources for VENU’s expansion, mitigating balance sheet risk while accelerating growth.

Expanding to Meet Booming Live Entertainment Demand

The global live entertainment market is projected to reach $79.7 billion by 2030, growing at a 16.1% CAGR (ResearchAndMarkets). As VENU continues to expand into underserved, high-demand markets—including Broken Arrow, OK (Tulsa Market), Oklahoma City, OK, El Paso, TX, and McKinney, TX—this new financing model is designed to expedite suite sales, ensuring broader access to ownership while reinforcing the Company’s capital-efficient expansion approach.

The Company currently operates premium entertainment venues in Colorado Springs, CO, and Gainesville, GA. VENU’s development pipeline includes five additional new markets in the design and development phase, setting the stage for accelerating growth.

For more information on Fire Pit Suite ownership opportunities and financing options, visit venu.live

About Venu Holding Corporation

Venu Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience.

VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents and NFL Hall of Famer and Founder of EIGHT Elite Light Lager, Troy Aikman, VENU continues to shape the future of the entertainment landscape.

Venu Holding Corporation Expands to Year-Round Operations with Multi-Season Venue Configuration, Unlocking New Revenue Growth

 

Source:  Venu Holding Corporation 2/18/2025

Strategic Expansion Designed to Maximize Revenue, Increase Margins, and Enhance Shareholder Value

Venu Holding Corporation ("VENU" or the “Company”) (NYSE American: VENU), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, today announced its launch of its multi-season venue configuration model for its new amphitheaters, a transformative shift that extends operational capacity from seasonal schedules to year-round operations and revenue potential. With this initiative, VENU-owned venues that are under construction or planned in McKinney, TX; El Paso, TX; Broken Arrow, OK; and Oklahoma City, OK will include design features and enhancements that allow them to operate and host events throughout each calendar year, increasing the number of events hosted annually at each venue and enhancing operational efficiency.  

Expanding Revenue & Profitability

By integrating climate-controlled environments, adaptable staging, and premium guest accommodations, VENU expects that when its new amphitheaters open it will be able to operate and monetize these venues year-round, reducing downtime and optimizing earnings potential. This strategy is expected to drive higher ticket sales, increased sponsorships, stronger food and beverage revenues, and additional revenue from parking and premium experiences, resulting in higher margins and long-term financial sustainability all while maintaining VENU’s signature premium ambiance.

“It’s simple math—more shows mean more revenue—but this isn’t just about quantity, it’s about a complete transformation,” Said J.W. Roth Founder, Chairman, and CEO of VENU. “We’re not just extending our schedule; we’re turning every season into peak season and unlocking millions in additional revenue potential. From increased ticket sales and sponsorships to high-end hospitality and premium guest experiences, we’re ensuring every aspect of our venues is optimized for profitability, while balancing risk and maximizing margins. VENU is proving that our business model isn’t just sustainable—it’s a game-changer in the live entertainment industry."

Capitalizing on a Booming Live Entertainment Market

VENU’s expansion aligns with strong industry growth projections. The ticket revenue segment of the live entertainment industry is expected to reach $65.2 billion by 2030, growing at a 16.4% compound annual growth rate (CAGR), while sponsorship revenues are forecasted to grow at 15.1% CAGR over the same period (Research And Markets). As consumer demand for premium live entertainment experiences surges, VENU’s ability to operate year-round strengthens its market position, enhances revenue predictability, and reinforces its long-term growth potential.

VENU’s Business Model: Seven Revenue Streams Driving Growth

VENU’s innovative business model leverages seven distinct revenue streams, reinforcing its position as a disruptive force in the live entertainment industry. The Company generates income through sponsorships and brand partnerships, including naming rights and in-venue sponsorship activations. Ticket sales and associated fees play a crucial role in revenue generation, further amplified by VENU’s expanded multi-season operating capacity. In addition, food and beverage sales from upscale dining and beverage service enhance revenue across VENU’s facilities. The Company also benefits from parking fees and venue rentals, generating further revenue from event-driven demand. Fee income, derived from strategic partnerships, licensing agreements, and premium hospitality services, provides an additional high-margin revenue stream. This diversified approach strengthens VENU’s financial stability by reducing reliance on any single revenue source while optimizing profitability across its entertainment campuses.

About Venu Holding Corporation

Venu Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience.

VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents and NFL Hall of Famer and Founder of EIGHT Elite Light Lager, Troy Aikman, VENU continues to shape the future of the entertainment landscape.

Venu Holding Corporation Achieves Another Record Month with $10.4 Million in January Fire Pit Suite Sales

 

Source:  Venu Holding Corporation 2/3/2025

 Company on Track for $200 Million for 2025

Venu Holding Corporation (“VENU” or “The Company”) (NYSE American: VENU), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, announced that in January, it achieved another record in luxury Fire Pit Suite sales. The Company’s January Fire Pit Suite sales exceeded $10.4 million, advancing toward their $200 million sales goal for fiscal 2025. This strong performance underscores VENU’s unique and de-risked financing strategy, which combines pre-sold luxury suites, public-private partnerships with municipalities, and long-term revenue-generating operating agreements with industry leaders such as AEG.  

“Our business model is built on three strategic steps,” says VENU Founder, Chairman, and CEO J.W. Roth. “First, we secure local municipal contributions for land, development, and infrastructure costs. Second, we pre-sell luxury Fire Pit Suites, using these funds to finance construction while significantly decreasing our reliance on debt financing and improving profitability and cash flow. Finally, once operational, we drive long-term ticket sales revenue with our operating partners, such as AEG Presents Rocky Mountains, alongside revenue from upscale food, beverage, premium parking, and sponsorship. We have seen this model thrive at Ford Amphitheater in Colorado Springs, and it continues to fuel our success.”

Fire Pit Suites remain among the most coveted ownership opportunities in the industry, offering lifetime access to every concert at a given venue, premium hospitality, meet-and-greet experiences, VIP amenities, and a multi-revenue stream return potential. With availability limited and demand at an all-time high, investors are securing these opportunities at a record pace.

Building on the momentum from a strong December, where Fire Pit Suite sales surpassed $11 million, the record-setting start to 2025 further solidifies VENU’s model of transforming live entertainment through premium ownership experiences. The surge in sales underscores the strength of VENU’s market positioning, driven by the company’s unique strategy that integrates high-demand real estate investments with live music entertainment.

VENU’s Business Model: Seven Revenue Streams Driving Growth

Beyond Fire Pit Suite sales, VENU’s innovative business model leverages seven distinct revenue streams, reinforcing its position as a disruptive force in the live entertainment industry. The company generates substantial income through sponsorships, securing strategic brand partnerships that include naming rights and in-venue sponsorship activations. Ticket sales and fees contribute significantly, driven by national touring acts, VIP experiences, and premium seating options. Food and beverage sales from upscale dining and beverage service further enhance revenue across VENU’s facilities. Additionally, VENU generates revenues from parking fees and venue rentals, as well as fee income, derived from strategic partnerships, licensing agreements, and premium hospitality services.

Public-Private Partnerships: A Capital-Efficient Growth Strategy

Unlike traditional entertainment venue developers that rely on extensive debt financing, VENU has pioneered a unique public-private partnership model. By collaborating with local municipalities and securing financial incentives, the Company strategically reduces upfront capital expenditures, allowing for sustainable expansion without burdening the balance sheet. Additionally, the pre-sale of naming rights, sponsorships, and suite ownerships further funds construction and operational development.

Expanding to Meet Demand

VENU’s growth strategy is focused on key underserved markets with high entertainment demand. The Company currently operates premium entertainment venues in Colorado Springs, CO, and Gainesville, GA, with an additional $2 billion in active construction and new market development including Broken Arrow, OK (Tulsa Market), Oklahoma City, OK, El Paso, TX, and McKinney, TX. With five additional new markets in the design and development phase, VENU has set the stage for continued growth. Once operational, the total seating inventory is expected to exceed 150,000 seats, accommodating up to 60 shows per year. This translates to approximately 10 million sellable seats annually. With 7 anticipated revenue channels VENU’s annual gross receipts could surpass $1.5 billion all while potentially seeing the addition of $2 billion in net tangible, mark to market assets.

As VENU continues to elevate the luxury entertainment experience, its business model, revenue diversity, and innovative funding strategies solidify its position as a leader in the evolving live entertainment landscape.

About Venu Holding Corporation

Venu Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience.

VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents and NFL Hall of Famer and Founder of EIGHT Elite Light Lager, Troy Aikman, VENU continues to shape the future of the entertainment landscape.

Venu Holding Corporation Closes on Property in McKinney, TX, Setting the Stage for 20,000-Seat, $300M Ultra-Lux Sunset Amphitheater

Source:  Venu Holding Corporation 1/15/2025

 Official Groundbreaking Ceremony Anticipated for Spring 2025

 

Venu Holding Corporation ("VENU" or “The Company”) (NYSE American: VENU), a leading premium hospitality and live entertainment company built by music fans for music fans, has closed on the 46-acre property for its 20,000-seat world-class outdoor music venue in McKinney, TX, The Sunset Amphitheater at McKinney powered by EIGHT Elite Light Beer (“EIGHT”). The official Groundbreaking Ceremony is anticipated for Spring 2025.  

The development of the premium destination is set to be built as part of a public-private partnership between VENU, the City of McKinney, the McKinney Economic Development Corporation, and the McKinney Community Development Corporation. Located in one of America’s fastest-growing cities, just northeast of Dallas-Fort Worth off Interstate 75 and Highway 121, the ultra-lux venue is poised to become a landmark in the region.

“This world-class music venue is a game-changer for our entertainment offerings in McKinney and will be a boom for our economic growth and tourism sector. With a state-of-the-art venue of this size, we can draw some of the largest musical acts to the city and attract fans from across Texas and the surrounding states,” said Mayor of McKinney, George Fuller. “This new addition to our community will bring even more life and energy to our already thriving arts scene and undoubtedly continue to set McKinney apart as an entertainment and cultural hub in the region.”

“We are proud to be building the greatest amphitheater ever built in history right here in the Center of the Universe, McKinney, TX,” said J.W. Roth Founder, Chairman, and CEO of VENU. “The Sunset Amphitheater at McKinney will defy all expectations, and we couldn’t be prouder to partner with The City of McKinney and their fearless rock-and-roll Mayor, George Fuller. It is truly a privilege to work together in creating a lasting legacy that all the people of McKinney and greater Dallas can take pride in.”

The Sunset Amphitheater at McKinney, powered by EIGHT Elite Light Beer, is set to redefine the live entertainment experience, breaking boundaries as a venue unlike any ever built.

Designed with fans at its heart, the amphitheater introduces music fans to unparalleled experiences. VENU’s innovative Fire Pit Suites provide a revolutionary way to experience live performances with your favorite artist. Each suite, seating between 4 and 10 fans based on investment level, includes access to premium food and beverages, complimentary VIP priority parking, and dedicated restrooms. These exclusive suites are now available for investment—once they're gone, they're gone.

Further, In collaboration with NFL Hall of Famer and EIGHT Founder Troy Aikman, the venue boasts The Aikman Club—a beautifully appointed members-only club offering world-class cuisine and nestled at the very center of the amphitheater. This one-of-a-kind space offers unmatched views, premium seating, and an array of high-end amenities for its elite members.

Troy Aikman, Founder of EIGHT Elite Light Beer and NFL Hall of Famer, said "I’m thrilled that VENU is opening a location here in my hometown of Dallas. As a lifelong music fan, the partnership between EIGHT and VENU is a special one to me. Nothing pairs better than great music and a cold beer, and I can’t wait for fans to enjoy both in an unforgettable way."

McKinney’s thriving arts, recreation, and tourism scene makes it an ideal match for Colorado-based VENU, a company redefining live entertainment by bringing grand-scale amphitheaters to flourishing cities. With operating venues in Gainesville, GA, and Colorado Springs, CO, and $1.3 billion in active site development and construction in Broken Arrow, OK (Tulsa Market), Oklahoma City, OK, El Paso, TX, and McKinney, TX, VENU is poised for significant expansion. With $200 million in projected Fire Pit Suite sales for 2025 and five additional markets in pre-construction, the Company is paving the way for sustained growth as it continues to shape the future of the entertainment landscape.

About Venu Holding Corporation

Venu Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience.

VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents and NFL Hall of Famer and Founder of EIGHT Elite Light Beer, Troy Aikman, VENU continues to shape the future of the entertainment landscape.